- Report
- March 2025
- 187 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- October 2024
- 197 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- October 2024
Global
From €3185EUR$3,500USD£2,731GBP
Amikacin is an aminoglycoside antibiotic used to treat a wide range of bacterial infections. It is effective against both gram-positive and gram-negative bacteria, and is often used in combination with other antibiotics. Amikacin is typically administered intravenously or intramuscularly, and is available in both generic and branded formulations. It is commonly used to treat infections of the urinary tract, respiratory tract, and skin and soft tissue.
Amikacin is a widely used antibiotic, and is available in many countries around the world. It is often used in combination with other antibiotics, and is generally well tolerated with few side effects. It is also relatively inexpensive, making it an attractive option for treating bacterial infections.
Some companies in the Amikacin market include Pfizer, Merck, Sanofi, GlaxoSmithKline, and Novartis. Show Less Read more